Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decitabine in acute myeloid leukemia.

Michael Lübbert1, Mark Minden

  • 1Department of Medicine, Division of Hematology/Oncology, University of Freiburg Medical Center, Freiburg, Germany. luebbert@mm11.ukl.uni-freiburg.de

Seminars in Hematology
|July 15, 2005
PubMed
Summary

Novel demethylating agents show promise for acute myeloid leukemia (AML) patients, especially the elderly or those with poor prognoses. These agents target epigenetic changes, offering an alternative to conventional chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Blood neoplasia·2026
Same author

A multimodal atlas for immunotherapeutic targeting of AML surface heterogeneity.

iScience·2026
Same author

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.

Annals of hematology·2026
Same author

Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?

Leukemia·2026
Same author

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Current oncology (Toronto, Ont.)·2026
Same author

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Blood·2026

Area of Science:

  • Hematology
  • Oncology
  • Epigenetics

Background:

  • Standard induction chemotherapy is the primary treatment for acute myeloid leukemia (AML) in patients under 75.
  • A significant portion of AML patients, particularly the elderly, cannot tolerate standard chemotherapy.
  • Novel treatment strategies are needed for both elderly patients and younger patients with poor-risk cytogenetics.

Purpose of the Study:

  • To review epigenetic processes in AML.
  • To explore the role of demethylating agents, specifically 5-aza-2 -deoxycytidine (decitabine), in AML treatment.
  • To discuss the potential of hypomethylating agents as novel therapeutic options.

Main Methods:

  • Review of current literature on epigenetic modifications in AML and myelodysplastic syndromes (MDS).

Related Experiment Videos

  • Examination of the mechanism of action of demethylating agents.
  • Discussion of preliminary results and future research directions for decitabine in AML.

    • Main Results:

    • Encouraging results from low-dose demethylating agents in MDS suggest potential for AML.
    • Demethylating agents target the DNA methylator phenotype in AML by reverting hypermethylation.
    • Decitabine is a key demethylating agent being investigated for AML treatment.

    Conclusions:

    • Demethylating agents represent a promising novel therapeutic approach for AML, particularly for patient groups not suited for conventional chemotherapy.
    • Further research is required to understand the role of target genes and optimize combination therapies involving hypomethylating agents.
    • Decitabine's epigenetic mechanism offers a biologically rational alternative to traditional cytotoxic chemotherapy in AML management.